Literature DB >> 9175728

Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice.

R A Williamson1, M D Henry, K J Daniels, R F Hrstka, J C Lee, Y Sunada, O Ibraghimov-Beskrovnaya, K P Campbell.   

Abstract

Dystroglycan is a central component of the dystrophin-glycoprotein complex (DGC), a protein assembly that plays a critical role in a variety of muscular dystrophies. In order to better understand the function of dystroglycan in development and disease, we have generated a null allele of dystroglycan (Dag1neo2) in mice. Heterozygous Dag1neo2 mice are viable and fertile. In contrast, homozygous Dag1neo2 embryos exhibit gross developmental abnormalities beginning around 6.5 days of gestation. Analysis of the mutant phenotype indicates that an early defect in the development of homozygous Dag1neo2 embryos is a disruption of Reichert's membrane, an extra-embryonic basement membrane. Consistent with the functional defects observed in Reichert's membrane, dystroglycan protein is localized in apposition to this structure in normal egg cylinder stage embryos. We also show that the localization of two critical structural elements of Reichert's membrane--laminin and collagen IV--are specifically disrupted in the homozygous Dag1neo2 embryos. Taken together, the data indicate that dystroglycan is required for the development of Reichert's membrane. Furthermore, these results suggest that disruption of basement membrane organization might be a common feature of muscular dystrophies linked to the DGC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175728     DOI: 10.1093/hmg/6.6.831

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  151 in total

1.  Division of labor among the alpha6beta4 integrin, beta1 integrins, and an E3 laminin receptor to signal morphogenesis and beta-casein expression in mammary epithelial cells.

Authors:  J Muschler; A Lochter; C D Roskelley; P Yurchenco; M J Bissell
Journal:  Mol Biol Cell       Date:  1999-09       Impact factor: 4.138

2.  Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins.

Authors:  J F Talts; Z Andac; W Göhring; A Brancaccio; R Timpl
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

Review 3.  Heparan sulfate: lessons from knockout mice.

Authors:  E Forsberg; L Kjellén
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

4.  Akt/PKB regulates laminin and collagen IV isotypes of the basement membrane.

Authors:  X Li; U Talts; J F Talts; E Arman; P Ekblom; P Lonai
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

Review 5.  Order and disorder: the role of extracellular matrix in epithelial cancer.

Authors:  Derek Radisky; John Muschler; Mina J Bissell
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

Review 6.  Epithelial mesenchymal interactions, the ECM and limb development.

Authors:  Peter Lonai
Journal:  J Anat       Date:  2003-01       Impact factor: 2.610

7.  Direct interaction of beta-dystroglycan with F-actin.

Authors:  Yun-Ju Chen; Heather J Spence; Jacqueline M Cameron; Thomas Jess; Jane L Ilsley; Steven J Winder
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

8.  Receptor use by the Whitewater Arroyo virus glycoprotein.

Authors:  Therese Reignier; Jill Oldenburg; Meg L Flanagan; Genevieve A Hamilton; Vanessa K Martin; Paula M Cannon
Journal:  Virology       Date:  2007-11-13       Impact factor: 3.616

Review 9.  The dystroglycanopathies: the new disorders of O-linked glycosylation.

Authors:  Paul T Martin
Journal:  Semin Pediatr Neurol       Date:  2005-09       Impact factor: 1.636

10.  Cloning and expression patterns of dystroglycan during the early development of Xenopus laevis.

Authors:  Nicole Moreau; Dominique Alfandari; Alban Gaultier; Hélène Cousin; Thierry Darribère
Journal:  Dev Genes Evol       Date:  2003-05-09       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.